𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study

✍ Scribed by Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Maria Gabriella Ceravolo

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
65 KB
Volume
21
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (TimexGroup effect: P<0.01), as well as in saliva production (Time x Group effect: P<0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD-related drooling.

πŸ“œ SIMILAR VOLUMES

Double-blind, placebo-controlled study t
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism
✍ Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 66 KB πŸ‘ 2 views

## Abstract Drooling is a frequent symptom in Parkinson's disease (PD), occurring in almost 75% of all patients. Although it is now well known that drooling in PD is the result of swallowing difficulties rather than excessive saliva production, few treatments have been developed to reduce it. Clini

Comparison of desipramine and citalopram
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 118 KB πŸ‘ 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

The effect of injecting botulinum toxin
The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo-controlled pilot study
✍ Tanya Gurevich; Chava Peretz; Orna Moore; Nina Weizmann; Nir Giladi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 61 KB

## Abstract ## Objective To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients. ## Method BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assess

Rotigotine transdermal patch in early Pa
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
✍ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 167 KB

## Abstract Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,

Levodopa improves physical fatigue in Pa
Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study
✍ Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 110 KB

## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi